Insider Brief
- Multiply Labs has entered into an agreement with AstraZeneca to evaluate GMP-ready robotic systems for automating commercial-scale cell therapy manufacturing while meeting regulatory and quality requirements.
- The collaboration will assess whether Multiply Labs’ autonomous platform can automate end-to-end operation of industry-standard cell therapy instruments with minimal changes to existing processes.
- Multiply Labs’ multi-arm robotic clusters are designed to run current manufacturing equipment in parallel to improve throughput and consistency within existing facilities.
Multiply Labs has entered into an agreement with AstraZeneca to evaluate the use of GMP-ready robotic systems for commercial-scale cell therapy manufacturing. According to the company, the collaboration will assess whether Multiply Labs’ autonomous robotic platform can automate end-to-end operation of industry-standard cell therapy instruments while meeting regulatory and quality requirements for clinical and commercial production.
“Cell therapies are among the most promising, yet complex medicines being developed today,” Fred Parietti, PhD, said in the announcement “Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale. This agreement with AstraZeneca allows us to evaluate our multi-arm robotic clusters in a setting where we can combine some of the world’s best scientific and clinical expertise with our robotic platform to build the next generation of high-throughput, GMP-ready cell therapy manufacturing.”
The San Francisco–based company said the work will focus on deploying multi-arm robotic clusters designed to run existing manufacturing equipment with minimal process changes, aiming to improve throughput and consistency in current facilities.
Multiply Labs’ latest systems use four robotic arms operating in parallel to run a range of cell therapy manufacturing instruments already used across the industry. The design is intended to limit process changes while increasing throughput in existing production facilities.
